"Current treatment of myelofibrosis based on risk stratification of patients"@en . "RIV/00098892:_____/13:#0000446" . "Szotkowski, Tom\u00E1\u0161" . "106491" . "[ABA7FD185D48]" . . "Sou\u010Dasn\u00E1 l\u00E9\u010Dba myelofibr\u00F3zy na z\u00E1klad\u011B rizikov\u00E9 stratifikace pacient\u016F" . . . . . "Hlu\u0161\u00ED, Anton\u00EDn" . . . "1213-5763" . . "I, S" . "Current treatment of myelofibrosis based on risk stratification of patients"@en . . "CZ - \u010Cesk\u00E1 republika" . . . "Prim\u00E1rni myelofibr\u00F3za je \u0159azena do skupiny chronick\u00FDch Ph1-negativn\u00EDch myeloproliferativn\u00EDch chorob spolu s esenci\u00E1ln\u00ED trombocytemi\u00ED a proavou polycytemi\u00ED, kter\u00E9 ve sv\u00E9m pr\u016Fb\u011Bhu takt\u00E9\u017E mohou p\u0159ech\u00E1zet do fibrotick\u00E9ho stadia. Rizikov\u00E1 stratifikace t\u011Bchto pacient\u016F m\u00E1 velk\u00FD v\u00FDznam pro spr\u00E1vn\u011B nastaven\u00E9 terapeutick\u00E9 rozhodnut\u00ED a pom\u00E1h\u00E1 selektovat vysoce rizikov\u00E9 nemocn\u00E9 vhodn\u00E9 k alogenn\u00ED transplantaci krvetvorn\u00FDch bun\u011Bk, kter\u00E1 i nad\u00E1le z\u016Fst\u00E1v\u00E1 jedinou kurativn\u00ED l\u00E9\u010Debnou modalitou myelofibr\u00F3zy. Transplanta\u010Dn\u00ED p\u0159\u00EDstup je pro v\u00FDznamnou mortalitu a morbiditu doporu\u010Dov\u00E1n u pacient\u016F s pravd\u011Bpodobn\u00FDm medi\u00E1nem p\u0159e\u017Eit\u00ED karat\u0161\u00EDm ne\u017E 5 let. Recentn\u011B uj\u017E\u00ED\u00E9van\u00E9 dynamick\u00E9 prognostick\u00E9 sk\u00F3re The Dynamic International Prognostic Scoring System-plus hodnot\u00ED osm nez\u00E1visl\u00FDch rizikov\u00FDch faktor\u016F zhor\u0161uj\u00EDc\u00EDch progn\u00F3zu. Do terapie myelofibr\u00F3zy je nov\u011B zav\u00E1d\u011Bna c\u00EDlen\u00E1 l\u00E9\u010Dba zasahuj\u00EDc\u00ED patogenetick\u00E9 sign\u00E1ln\u00ED dr\u00E1hy, jej\u00EDmi\u017E p\u0159edsstaviteli jsou inhibitory Janus 2 kin\u00E1zy. Jejich \u00FA\u010Dinnost, bezpe\u010Dnost a vliv na celkov\u00E9 p\u0159e\u017Eit\u00ED z dlouhodob\u011Bj\u0161\u00EDho hlediska uk\u00E1\u017E\u00ED a\u017E v\u00FDsledky prob\u00EDhaj\u00EDc\u00EDch studi\u00ED."@cs . . "2"^^ . "Primary myelofibrosis belongs to the group od Ph1-negative myeloproliferative neoplasms, along with essential thrombocythemia and polycythemia vera, which may also progress to a fibrotic stage. Risk stratification of patients is especially important for proper therapeutic decision making and selection of high risk patients suitable for allogeneic stem cell transplantation, the only curative option for myelofibrosis. Transplantation carries a significant risk of mortality and morbidity, therefore it is recommended in patients with a median survival of less than 5 years. The recently introduced Dynamic International Prognostic Scoring System-plus prognostic model uses eight independent predictors of inferior survival. Janus 2 kinase inhibitors present a new targeted therapy affecting pathogenetic signal pathways. The result of on-going studies will show their long-term efficacy, safety and impact on overall survival."@en . "Sou\u010Dasn\u00E1 l\u00E9\u010Dba myelofibr\u00F3zy na z\u00E1klad\u011B rizikov\u00E9 stratifikace pacient\u016F"@cs . "RIV/00098892:_____/13:#0000446!RIV14-MZ0-00098892" . "4"^^ . . . "Sou\u010Dasn\u00E1 l\u00E9\u010Dba myelofibr\u00F3zy na z\u00E1klad\u011B rizikov\u00E9 stratifikace pacient\u016F"@cs . . "myelofibrosis, splenomegaly, JAK2V617F mutation, JAK2 inhibitors"@en . "Prim\u00E1rni myelofibr\u00F3za je \u0159azena do skupiny chronick\u00FDch Ph1-negativn\u00EDch myeloproliferativn\u00EDch chorob spolu s esenci\u00E1ln\u00ED trombocytemi\u00ED a proavou polycytemi\u00ED, kter\u00E9 ve sv\u00E9m pr\u016Fb\u011Bhu takt\u00E9\u017E mohou p\u0159ech\u00E1zet do fibrotick\u00E9ho stadia. Rizikov\u00E1 stratifikace t\u011Bchto pacient\u016F m\u00E1 velk\u00FD v\u00FDznam pro spr\u00E1vn\u011B nastaven\u00E9 terapeutick\u00E9 rozhodnut\u00ED a pom\u00E1h\u00E1 selektovat vysoce rizikov\u00E9 nemocn\u00E9 vhodn\u00E9 k alogenn\u00ED transplantaci krvetvorn\u00FDch bun\u011Bk, kter\u00E1 i nad\u00E1le z\u016Fst\u00E1v\u00E1 jedinou kurativn\u00ED l\u00E9\u010Debnou modalitou myelofibr\u00F3zy. Transplanta\u010Dn\u00ED p\u0159\u00EDstup je pro v\u00FDznamnou mortalitu a morbiditu doporu\u010Dov\u00E1n u pacient\u016F s pravd\u011Bpodobn\u00FDm medi\u00E1nem p\u0159e\u017Eit\u00ED karat\u0161\u00EDm ne\u017E 5 let. Recentn\u011B uj\u017E\u00ED\u00E9van\u00E9 dynamick\u00E9 prognostick\u00E9 sk\u00F3re The Dynamic International Prognostic Scoring System-plus hodnot\u00ED osm nez\u00E1visl\u00FDch rizikov\u00FDch faktor\u016F zhor\u0161uj\u00EDc\u00EDch progn\u00F3zu. Do terapie myelofibr\u00F3zy je nov\u011B zav\u00E1d\u011Bna c\u00EDlen\u00E1 l\u00E9\u010Dba zasahuj\u00EDc\u00ED patogenetick\u00E9 sign\u00E1ln\u00ED dr\u00E1hy, jej\u00EDmi\u017E p\u0159edsstaviteli jsou inhibitory Janus 2 kin\u00E1zy. Jejich \u00FA\u010Dinnost, bezpe\u010Dnost a vliv na celkov\u00E9 p\u0159e\u017Eit\u00ED z dlouhodob\u011Bj\u0161\u00EDho hlediska uk\u00E1\u017E\u00ED a\u017E v\u00FDsledky prob\u00EDhaj\u00EDc\u00EDch studi\u00ED." . "8"^^ . "19" . . "3" . . "Sou\u010Dasn\u00E1 l\u00E9\u010Dba myelofibr\u00F3zy na z\u00E1klad\u011B rizikov\u00E9 stratifikace pacient\u016F" . "Transfuze a hematologie dnes" . .